These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

535 related articles for article (PubMed ID: 26343800)

  • 1. The association between sterilizing activity and drug distribution into tuberculosis lesions.
    Prideaux B; Via LE; Zimmerman MD; Eum S; Sarathy J; O'Brien P; Chen C; Kaya F; Weiner DM; Chen PY; Song T; Lee M; Shim TS; Cho JS; Kim W; Cho SN; Olivier KN; Barry CE; Dartois V
    Nat Med; 2015 Oct; 21(10):1223-7. PubMed ID: 26343800
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimizing treatment outcome of first-line anti-tuberculosis drugs: the role of therapeutic drug monitoring.
    Verbeeck RK; Günther G; Kibuule D; Hunter C; Rennie TW
    Eur J Clin Pharmacol; 2016 Aug; 72(8):905-16. PubMed ID: 27305904
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Delamanid Kills Dormant Mycobacteria
    Chen X; Hashizume H; Tomishige T; Nakamura I; Matsuba M; Fujiwara M; Kitamoto R; Hanaki E; Ohba Y; Matsumoto M
    Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28373190
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological and Molecular Mechanisms Behind the Sterilizing Activity of Pyrazinamide.
    Gopal P; Grüber G; Dartois V; Dick T
    Trends Pharmacol Sci; 2019 Dec; 40(12):930-940. PubMed ID: 31704175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancement of in vitro activity of tuberculosis drugs by addition of thioridazine is not reflected by improved in vivo therapeutic efficacy.
    de Knegt GJ; ten Kate MT; van Soolingen D; Aarnoutse R; Boeree MJ; Bakker-Woudenberg IA; de Steenwinkel JE
    Tuberculosis (Edinb); 2014 Dec; 94(6):701-7. PubMed ID: 25621361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of rifapentine and rifampin in a rabbit model of tuberculosis and correlation with clinical trial data.
    Rifat D; Prideaux B; Savic RM; Urbanowski ME; Parsons TL; Luna B; Marzinke MA; Ordonez AA; DeMarco VP; Jain SK; Dartois V; Bishai WR; Dooley KE
    Sci Transl Med; 2018 Apr; 10(435):. PubMed ID: 29618565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fighting tuberculosis by drugs targeting nonreplicating
    Iacobino A; Piccaro G; Giannoni F; Mustazzolu A; Fattorini L
    Int J Mycobacteriol; 2017; 6(3):213-221. PubMed ID: 28776518
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SILA-421 activity in vitro against rifampicin-susceptible and rifampicin-resistant Mycobacterium tuberculosis, and in vivo in a murine tuberculosis model.
    de Knegt GJ; Bakker-Woudenberg IA; van Soolingen D; Aarnoutse R; Boeree MJ; de Steenwinkel JE
    Int J Antimicrob Agents; 2015 Jul; 46(1):66-72. PubMed ID: 25951996
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the 'Denver regimen' against acute tuberculosis in the mouse and guinea pig.
    Ahmad Z; Nuermberger EL; Tasneen R; Pinn ML; Williams KN; Peloquin CA; Grosset JH; Karakousis PC
    J Antimicrob Chemother; 2010 Apr; 65(4):729-34. PubMed ID: 20123722
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Experimental evidence for Mycobacterium tuberculosis persistence in M. tuberculosis-infected H37RV mice in the treatment with 3 first-line drugs (rifampicin, isoniazid, pyrazinamide)].
    Smirnova TG; Chernousova LN; Andreevskaia SN; Nikolaeva GM
    Probl Tuberk Bolezn Legk; 2004; (3):32-7. PubMed ID: 15338898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extreme Drug Tolerance of Mycobacterium tuberculosis in Caseum.
    Sarathy JP; Via LE; Weiner D; Blanc L; Boshoff H; Eugenin EA; Barry CE; Dartois VA
    Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29203492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlations Between the Hollow Fiber Model of Tuberculosis and Therapeutic Events in Tuberculosis Patients: Learn and Confirm.
    Gumbo T; Pasipanodya JG; Nuermberger E; Romero K; Hanna D
    Clin Infect Dis; 2015 Aug; 61 Suppl 1():S18-24. PubMed ID: 26224768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimal doses of rifampicin in the standard drug regimen to shorten tuberculosis treatment duration and reduce relapse by eradicating persistent bacteria.
    Liu Y; Pertinez H; Ortega-Muro F; Alameda-Martin L; Harrison T; Davies G; Coates A; Hu Y
    J Antimicrob Chemother; 2018 Mar; 73(3):724-731. PubMed ID: 29244108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sterilizing activity of R207910 (TMC207)-containing regimens in the murine model of tuberculosis.
    Ibrahim M; Truffot-Pernot C; Andries K; Jarlier V; Veziris N
    Am J Respir Crit Care Med; 2009 Sep; 180(6):553-7. PubMed ID: 19590024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis.
    Mitchison DA; Nunn AJ
    Am Rev Respir Dis; 1986 Mar; 133(3):423-30. PubMed ID: 2420242
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Location of persisting mycobacteria in a Guinea pig model of tuberculosis revealed by r207910.
    Lenaerts AJ; Hoff D; Aly S; Ehlers S; Andries K; Cantarero L; Orme IM; Basaraba RJ
    Antimicrob Agents Chemother; 2007 Sep; 51(9):3338-45. PubMed ID: 17517834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spectinamides are effective partner agents for the treatment of tuberculosis in multiple mouse infection models.
    Robertson GT; Scherman MS; Bruhn DF; Liu J; Hastings C; McNeil MR; Butler MM; Bowlin TL; Lee RB; Lee RE; Lenaerts AJ
    J Antimicrob Chemother; 2017 Mar; 72(3):770-777. PubMed ID: 27999020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Pharmacokinetics and Pharmacodynamics of Rifampicin in Human Tuberculosis.
    Abulfathi AA; Decloedt EH; Svensson EM; Diacon AH; Donald P; Reuter H
    Clin Pharmacokinet; 2019 Sep; 58(9):1103-1129. PubMed ID: 31049868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rifapentine is not more active than rifampin against chronic tuberculosis in guinea pigs.
    Dutta NK; Illei PB; Peloquin CA; Pinn ML; Mdluli KE; Nuermberger EL; Grosset JH; Karakousis PC
    Antimicrob Agents Chemother; 2012 Jul; 56(7):3726-31. PubMed ID: 22547623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rationale for chemotherapy of tuberculosis and current recommendations.
    Kumar L
    Indian Pediatr; 1992 Nov; 29(11):1337-9. PubMed ID: 1294486
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 27.